title: Management of diabetic and hypertensive cardiovascular disease.
abstract: The simultaneous occurrence of essential hypertension and diabetes mellitus is exceedingly common. In recent years the treatment of the cardiovascular and renal complications has not only become more specific but more effective. The evidence-based medicine data have been provided through many large multicenter studies and strongly support the promise not only of effective treatment in retarding the progression of target-organ involvement, but also the potential of reversal. These dramatic therapeutic improvements have been made possible by wedding the involved pathophysiologic disease mechanisms with the actions of pharmacologic agents. Inherent in this concept is the promise of retarding the development of the cardiovascular and renal morbid events and also reducing their associated mortal endpoints.
authors.affiliation: Ochsner Clinic Foundation, 1516 Jefferson Highway, New Orleans, LA 70121, USA. efrohlich@ochsner.org
authors.forename: Edward D
authors.initials: ED
authors.lastname: Frohlich
authors.forename: James R
authors.initials: JR
authors.lastname: Sowers
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000503:physiopathology*; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000503:physiopathology*; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists